PBAC's latest decision on Sodium zirconium cyclosilicate: Recommended with restriction (2024). Considered for Treatment of chronic hyperkalaemia in patients with chronic kidney disease Stage 3-4 who are receiving or indicated for renin angiotensin aldosterone system inhibitor (RAASi) medicines.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Adults with CKD stage 3-4 with chronic hyperkalaemia (≥2 episodes of serum potassium ≥6.0 mmol/L in the previous 12 months), receiving ≥1 RAASi medicine or indicated for RAASi but unable to tolerate due to prior hyperkalaemia, with disease inadequately controlled by low potassium diet.
Therapy area
Endocrinology
Line of therapy
Any
Evidence base
RCT
Primary endpoint
Serum potassium lowering / maintenance
Pivotal trial size
1,582 patients
Key trials
ZS004, ZS004e, ZS005, OPAL-HK, AMETHYST-DN
Comparator
patiromer sorbitex calcium
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis used; no ICER calculated by design.
Risk sharing
Risk-sharing arrangement in place — Special pricing arrangements apply, consistent with patiromer listing.